August 2, 2011
The implementation of new cardiac drug safety requirements by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) could help to establish whether and in what way ethnicity impacts drug-induced proarrhythmic liability, according to a study1 published in International Pharmaceutical Industry.
Log in or Register now.
Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.